Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Korea Otsuka Pharmaceutical Co.,Ltd. |
---|---|
Information provided by: | Korea Otsuka Pharmaceutical Co.,Ltd. |
ClinicalTrials.gov Identifier: | NCT00304616 |
To evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Randomized, Open, Treatment-Switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients |
Estimated Enrollment: | 500 |
Study Start Date: | October 2004 |
Estimated Study Completion Date: | July 2006 |
This trial was designed to evaluate the efficacy, safety and tolerance of an 12 and 26-week aripiprazole administration to schizophrenic outpatients who maintain stable (no change with dosage, usage, route of the most recent antipsychotic drugs) symptoms and discontinued previous antipsychotic drugs.
Aripiprazole (10~30 mg/day) will be orally administered for 12 weeks followed by an extension phase for a maximum of an additional 14 weeks (total of 26 weeks).
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |
Asan Medical Center | |
Seoul, Korea, Republic of, 138-736 |
Principal Investigator: | Chang-Yoon Kim, Prof. | Asan Medical Center |
Study ID Numbers: | KOP-010402 |
Study First Received: | March 17, 2006 |
Last Updated: | July 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00304616 |
Health Authority: | Korea: Institutional Review Board |
Schizophrenia Aripiprazole |
Schizophrenia Quetiapine Dopamine Mental Disorders Sultopride Risperidone |
Olanzapine Psychotic Disorders Aripiprazole Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |